首页 > 最新文献

Chest最新文献

英文 中文
Response.
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.10.009
Christopher D Barrett, Peter K Moore, Michael B Yaffe
{"title":"Response.","authors":"Christopher D Barrett, Peter K Moore, Michael B Yaffe","doi":"10.1016/j.chest.2024.10.009","DOIUrl":"https://doi.org/10.1016/j.chest.2024.10.009","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"e64-e65"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405971","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
The Politicization of a Menthol Cigarette Ban in the United States: What the Medical and Public Health Workforce Can Do to Support Evidence-Based Policymaking.
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.08.025
Enid Neptune, Jennifer L Brown
{"title":"The Politicization of a Menthol Cigarette Ban in the United States: What the Medical and Public Health Workforce Can Do to Support Evidence-Based Policymaking.","authors":"Enid Neptune, Jennifer L Brown","doi":"10.1016/j.chest.2024.08.025","DOIUrl":"https://doi.org/10.1016/j.chest.2024.08.025","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"324-326"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405987","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Critical Care Psychiatry.
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.08.047
Melissa P Bui
{"title":"Critical Care Psychiatry.","authors":"Melissa P Bui","doi":"10.1016/j.chest.2024.08.047","DOIUrl":"https://doi.org/10.1016/j.chest.2024.08.047","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"571-572"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406165","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Diabetes and Cardiovascular Mortality Among Restrictive and Preserved Ratio Impaired Spirometry Phenotypes.
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.09.012
Lies Lahousse
{"title":"Diabetes and Cardiovascular Mortality Among Restrictive and Preserved Ratio Impaired Spirometry Phenotypes.","authors":"Lies Lahousse","doi":"10.1016/j.chest.2024.09.012","DOIUrl":"https://doi.org/10.1016/j.chest.2024.09.012","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"314-315"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406173","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Echocardiographic Image of Left Ventricular Thrombus Formation During Cardiac Contractility Recovery Under Extracorporeal Membrane Oxygenation Support.
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.08.030
Peng Wang, Yongfei He, Xiang Tan, Wenjuan Zhang, Min Yu
{"title":"Echocardiographic Image of Left Ventricular Thrombus Formation During Cardiac Contractility Recovery Under Extracorporeal Membrane Oxygenation Support.","authors":"Peng Wang, Yongfei He, Xiang Tan, Wenjuan Zhang, Min Yu","doi":"10.1016/j.chest.2024.08.030","DOIUrl":"https://doi.org/10.1016/j.chest.2024.08.030","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"e57-e62"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143406211","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Choosing the Right Biologic for the Right Patient With Severe Asthma. 我是怎么做的为重症哮喘患者选择合适的生物制剂。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-09-06 DOI: 10.1016/j.chest.2024.08.045
Simon Couillard, David J Jackson, Ian D Pavord, Michael E Wechsler

In this installment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma. With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omalizumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and benralizumab; anti-IL-4-receptor: dupilumab; anti-thymic stromal lymphopoietin: tezepelumab), this question is increasingly complex. Recognizing that no head-to-head trial has compared biologics, we based our review on the expected effects of inhibiting different aspects of type 2 airway inflammation, supported whenever possible by clinical trial and real-world data. We use four variations of a case of severe uncontrolled asthma to develop concepts and considerations introduced in the previous installment ("Workup of Severe Asthma") and discuss pregnancy-related, biomarker-related, comorbidity-related, and corticosteroid dependency-related considerations when choosing a biologic. The related questions of deciding when, why, and how to switch from one biologic to another also are discussed. Overall, we consider that the choice of biologics should be based on the available clinical trial data for the desired efficacy outcomes, the biomarker profile of the patient, safety profiles (eg, when pregnancy is considered), and opportunities to target two comorbidities with one biologic. Using systemic and airway biomarkers (blood eosinophils and exhaled nitric oxide [Feno]) and other phenotypic characteristics, we suggest a framework to facilitate therapeutic decision-making. Post hoc studies and new comparative studies are needed urgently to test this framework and to determine whether it allows us to make other clinically useful predictions.

在 "我是怎么做的:重症哮喘 "系列的新一期文章中,我们将探讨如何为重症哮喘患者选择合适的生物制剂这一临床难题。目前已有 6 种生物制剂获准用于该领域,包括 4 种不同的靶向策略(抗免疫球蛋白 E,奥马珠单抗;抗白细胞介素 (IL)-5/5 受体,mepolizumab、reslizumab 和 benralizumab;抗 IL-4 受体,dupilumab;抗胸腺基质淋巴细胞生成素,tezepelumab),因此这个问题变得越来越复杂。我们认识到目前还没有头对头比较生物制剂的试验,因此我们的综述以抑制 2 型气道炎症不同方面的预期效果为基础,并尽可能以临床试验和实际数据为支持。我们使用四种不同的重症未控制哮喘病例来阐释前一篇《重症哮喘分期治疗》中介绍的概念和注意事项,并讨论在选择生物制剂时与妊娠、生物标志物、合并症和皮质类固醇依赖相关的注意事项。我们还讨论了决定何时、为何以及如何从一种生物制剂转为另一种生物制剂的相关问题。总之,我们认为生物制剂的选择应基于以下因素:所需疗效的现有临床试验数据;患者的生物标志物特征;安全性特征(如考虑妊娠时);以及用一种生物制剂治疗两种合并症的机会。利用全身和气道生物标志物(血液嗜酸性粒细胞和呼出一氧化氮(FeNO))及其他表型特征,我们提出了一个有助于治疗决策的框架。我们亟需进行事后研究和新的比较研究来检验这一框架,并确定它是否能让我们做出其他临床有用的预测。
{"title":"Choosing the Right Biologic for the Right Patient With Severe Asthma.","authors":"Simon Couillard, David J Jackson, Ian D Pavord, Michael E Wechsler","doi":"10.1016/j.chest.2024.08.045","DOIUrl":"10.1016/j.chest.2024.08.045","url":null,"abstract":"<p><p>In this installment of the How I Do It series on severe asthma, we tackle the clinical conundrum of choosing the right biologic for the right patient with severe asthma. With six biologics now approved for use in this area comprising four different targeting strategies (anti-Ig E: omalizumab; anti-IL-5 and anti-IL-5-receptor: mepolizumab, reslizumab, and benralizumab; anti-IL-4-receptor: dupilumab; anti-thymic stromal lymphopoietin: tezepelumab), this question is increasingly complex. Recognizing that no head-to-head trial has compared biologics, we based our review on the expected effects of inhibiting different aspects of type 2 airway inflammation, supported whenever possible by clinical trial and real-world data. We use four variations of a case of severe uncontrolled asthma to develop concepts and considerations introduced in the previous installment (\"Workup of Severe Asthma\") and discuss pregnancy-related, biomarker-related, comorbidity-related, and corticosteroid dependency-related considerations when choosing a biologic. The related questions of deciding when, why, and how to switch from one biologic to another also are discussed. Overall, we consider that the choice of biologics should be based on the available clinical trial data for the desired efficacy outcomes, the biomarker profile of the patient, safety profiles (eg, when pregnancy is considered), and opportunities to target two comorbidities with one biologic. Using systemic and airway biomarkers (blood eosinophils and exhaled nitric oxide [Feno]) and other phenotypic characteristics, we suggest a framework to facilitate therapeutic decision-making. Post hoc studies and new comparative studies are needed urgently to test this framework and to determine whether it allows us to make other clinically useful predictions.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"330-342"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867899/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142153220","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure. 静息肺动脉压正常或轻度升高患者 TAPSE/sPAP 比值的预后相关性及其与运动血流动力学的联系。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-09-26 DOI: 10.1016/j.chest.2024.09.013
Teresa John, Alexander Avian, Nikolaus John, Antonia Eger, Vasile Foris, Katarina Zeder, Horst Olschewski, Manuel Richter, Khodr Tello, Gabor Kovacs, Philipp Douschan

Background: Echocardiographic tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary arterial pressure (sPAP) ratio is a noninvasive surrogate for right ventricle (RV)-pulmonary arterial (PA) coupling. It has been related to outcome in patients with moderate to severe pulmonary hypertension (PH).

Research question: Is RV-PA coupling of prognostic relevance in patients with suspected PH, but only normal or mildly elevated mean pulmonary arterial pressure (mPAP), and is it associated with impaired exercise capacity and exercise hemodynamics?

Study design and methods: Patients with mPAP of < 25 mm Hg who underwent echocardiography and exercise right heart catheterization in our PH clinic were analyzed retrospectively. Mild PH was defined as mPAP of 21 to 24 mm Hg and exercise PH (EPH) was defined as a mPAP to cardiac output (CO) slope of > 3 mm Hg/L/min. Multivariate analysis was performed to identify independent predictors for clinical worsening (CW), defined by disease-related hospitalization, transplantation, or death.

Results: Two hundred thirty-seven patients (155 female with median age, 64 years [interquartile range (IQR), 54-73 years]; no PH: n = 147; mild PH: n = 90; EPH: n = 202) were included. During the observation time of 63 months (IQR, 29-104 months), 36 patients died and 126 clinical worsening events occurred. TAPSE to sPAP ratio was an age- and sex-independent predictor of mortality (hazard ratio [HR], 0.09; 95% CI, 0.01-0.62; P = .014) and clinical worsening (HR, 0.05; 95% CI, 0.35-0.78; P = .002). TAPSE to sPAP ratio also was correlated significantly to 6-min walk distance (r = 0.33; P < .001) and exercise hemodynamics (mPAP to CO slope: rρ = -0.56; P < .001). The best multivariate predictive model for clinical worsening in this population consisted of TAPSE to sPAP ratio (HR, 0.71; 95% CI, 0.53-0.95; P = .021), N-terminal pro-brain natriuretic peptide (HR, 1.15; 95% CI, 0.99-1.34; P = .065), and 6-min walk distance (HR, 0.998; 95% CI, 0.995-1.00; P = .042).

Interpretation: Our results indicate that in patients with suspected PH, but normal or only mildly elevated resting mPAP, TAPSE to sPAP ratio is an independent predictor of outcome. In addition, it is associated significantly with exercise capacity and exercise hemodynamics and may be a helpful tool in the prediction of future clinical worsening of this patient population.

背景:超声心动图 TAPSE/sPAP 比值是右心室-肺动脉(RV-PA)耦合的无创替代指标。它与中重度肺动脉高压(PH)患者的预后有关:研究问题:对于怀疑患有 PH 但平均肺动脉压(mPAP)正常或轻度升高的患者,RV-PA 耦合是否与预后有关,是否与运动能力和运动血流动力学受损有关?mPAP3mmHg/L/min 的患者。结果:共纳入 237 例患者(女性:N=155;中位年龄:64(IQR 54-73)岁,无 PH N=147;轻度 PH N=90;EPH N=202)。在 63(IQR:29-104)个月的观察期间,36 名患者死亡,126 例临床恶化。TAPSE/sPAP 比值与年龄和性别无关,可预测死亡率(HR 0.09 95% CI: (0.01 - 0.62) p=0.014)和临床恶化(HR 0.05 95% CI: (0.35-0.78); p=0.002)。TAPSE/sPAP 与 6 分钟步行距离也有显著相关性(r= 0.33;pρ=-0.56,p解释:在疑似 PH 但静息 mPAP 正常或仅轻度升高的患者中,TAPSE/sPAP 比值是预测预后的独立指标。此外,TAPSE/sPAP 比值与运动能力和运动血流动力学显著相关,可能是预测这类患者未来临床恶化的有用工具。
{"title":"Prognostic Relevance of Tricuspid Annular Plane Systolic Excursion to Systolic Pulmonary Arterial Pressure Ratio and Its Association With Exercise Hemodynamics in Patients With Normal or Mildly Elevated Resting Pulmonary Arterial Pressure.","authors":"Teresa John, Alexander Avian, Nikolaus John, Antonia Eger, Vasile Foris, Katarina Zeder, Horst Olschewski, Manuel Richter, Khodr Tello, Gabor Kovacs, Philipp Douschan","doi":"10.1016/j.chest.2024.09.013","DOIUrl":"10.1016/j.chest.2024.09.013","url":null,"abstract":"<p><strong>Background: </strong>Echocardiographic tricuspid annular plane systolic excursion (TAPSE) to systolic pulmonary arterial pressure (sPAP) ratio is a noninvasive surrogate for right ventricle (RV)-pulmonary arterial (PA) coupling. It has been related to outcome in patients with moderate to severe pulmonary hypertension (PH).</p><p><strong>Research question: </strong>Is RV-PA coupling of prognostic relevance in patients with suspected PH, but only normal or mildly elevated mean pulmonary arterial pressure (mPAP), and is it associated with impaired exercise capacity and exercise hemodynamics?</p><p><strong>Study design and methods: </strong>Patients with mPAP of < 25 mm Hg who underwent echocardiography and exercise right heart catheterization in our PH clinic were analyzed retrospectively. Mild PH was defined as mPAP of 21 to 24 mm Hg and exercise PH (EPH) was defined as a mPAP to cardiac output (CO) slope of > 3 mm Hg/L/min. Multivariate analysis was performed to identify independent predictors for clinical worsening (CW), defined by disease-related hospitalization, transplantation, or death.</p><p><strong>Results: </strong>Two hundred thirty-seven patients (155 female with median age, 64 years [interquartile range (IQR), 54-73 years]; no PH: n = 147; mild PH: n = 90; EPH: n = 202) were included. During the observation time of 63 months (IQR, 29-104 months), 36 patients died and 126 clinical worsening events occurred. TAPSE to sPAP ratio was an age- and sex-independent predictor of mortality (hazard ratio [HR], 0.09; 95% CI, 0.01-0.62; P = .014) and clinical worsening (HR, 0.05; 95% CI, 0.35-0.78; P = .002). TAPSE to sPAP ratio also was correlated significantly to 6-min walk distance (r = 0.33; P < .001) and exercise hemodynamics (mPAP to CO slope: r<sub>ρ</sub> = -0.56; P < .001). The best multivariate predictive model for clinical worsening in this population consisted of TAPSE to sPAP ratio (HR, 0.71; 95% CI, 0.53-0.95; P = .021), N-terminal pro-brain natriuretic peptide (HR, 1.15; 95% CI, 0.99-1.34; P = .065), and 6-min walk distance (HR, 0.998; 95% CI, 0.995-1.00; P = .042).</p><p><strong>Interpretation: </strong>Our results indicate that in patients with suspected PH, but normal or only mildly elevated resting mPAP, TAPSE to sPAP ratio is an independent predictor of outcome. In addition, it is associated significantly with exercise capacity and exercise hemodynamics and may be a helpful tool in the prediction of future clinical worsening of this patient population.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"573-584"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11867897/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142342563","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States. 美国支气管镜肺容积缩小术的住院并发症发生率。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-08-23 DOI: 10.1016/j.chest.2024.08.012
Francisco F Costa Filho, Jonh D Buckley, Alan Furlan, Samantha Campbell, Kirsten Hickok, Philip J Kroth

Background: Early randomized controlled trials (RCTs) of bronchoscopic lung volume reduction (BLVR) have shown clinically meaningful benefits in lung function, dyspnea, and quality of life in patients with severe emphysema. Safety outcome data obtained after BLVR in the United States are scarce outside the RCTs.

Research question: What is the rate of inpatient complications after BLVR in the real world in the United States?

Study design and methods: We used the National Inpatient Sample database to identify in-hospital complications after BLVR from 2018 through 2020. Complications were defined as pneumothorax, COPD exacerbation, pneumonia, hemoptysis, acute respiratory failure, and valve removal. We also analyzed all-cause in-hospital mortality and length of stay (LOS).

Results: We identified 467 admissions related to BLVR procedures. The number of procedures doubled between 2019 and 2020 (from 153 to 295 procedures). The median age was 67.9 years (interquartile range, 61.1-72.8 years), 210 patients (45.0%) were female, 401 patients (85.8%) were White, and Medicare was the primary expected payer for 72.8% of patients. Most procedures were performed in urban teaching hospitals (56.9%). The rate of pneumothorax was 26.3%, that of acute respiratory failure was 19.5%, that of COPD exacerbation was 8.8%, that of pneumonia was 7.3%, and that of hemoptysis was 5.3%. Chest tube placement was required in 84 of 123 patients (68.3%) with pneumothorax. The endobronchial valve had to be removed in 69 patients (14.8%). The median LOS was 2.8 days (interquartile range, 2.3-4.5 days). The number of in-hospital deaths was fewer than 11 (< 2.3%). Overall, the subgroup who experienced in-hospital complications did not differ significantly from the others in terms of comorbidities, demographics, and hospital characteristics.

Interpretation: We found that the real-world complication rate after BLVR was similar to the published complication rates from early randomized clinical trials. In-hospital mortality was low, suggesting that aside from the commonly anticipated complications, BLVR is a safe treatment option for severe emphysema.

背景:支气管镜肺容积缩小术(BLVR)的早期随机对照试验(RCT)显示,严重肺气肿患者在肺功能、呼吸困难和生活质量方面获得了有临床意义的益处。在美国,除了 RCT 外,BLVR 的安全性结果数据很少:研究设计和方法:我们使用全国住院病人抽样(NIS)数据库来确定2018年至2020年BLVR术后的住院并发症。并发症定义为气胸、慢性阻塞性肺疾病加重、肺炎、咯血、急性呼吸衰竭和瓣膜摘除。我们还分析了全因住院死亡率和住院时间(LOS):我们确定了 467 例与 BLVR 程序相关的入院病例。2019年至2020年间,手术数量翻了一番(从153例增加到295例)。中位年龄为 67.9 岁(IQR 61.1 - 72.8),210 人(45.0%)为女性,401 人(85.8%)为白人,在 72.8% 的病例中,医疗保险是主要的预期付款人。大多数手术在城市教学医院完成(56.9%)。气胸发生率为 26.3%,急性呼吸衰竭发生率为 19.5%,慢性阻塞性肺疾病恶化发生率为 8.8%,肺炎发生率为 7.3%,咯血发生率为 5.3%。在 123 例气胸病例中,有 84 例(68.3%)需要放置胸管。69例(14.8%)患者需要移除支气管内瓣膜。住院时间中位数为 2.8 天(IQR 2.3 -4.5)。院内死亡病例少于 11 例(< 2.3%)。总体而言,出现院内并发症的亚组在合并症、人口统计学和医院特征方面与其他亚组没有显著差异:BLVR术后的实际并发症发生率与早期随机临床试验公布的并发症发生率相似。院内死亡率很低,这表明除了常见的预期并发症外,BLVR是治疗严重肺气肿的一种安全选择。
{"title":"Inpatient Complication Rates of Bronchoscopic Lung Volume Reduction in the United States.","authors":"Francisco F Costa Filho, Jonh D Buckley, Alan Furlan, Samantha Campbell, Kirsten Hickok, Philip J Kroth","doi":"10.1016/j.chest.2024.08.012","DOIUrl":"10.1016/j.chest.2024.08.012","url":null,"abstract":"<p><strong>Background: </strong>Early randomized controlled trials (RCTs) of bronchoscopic lung volume reduction (BLVR) have shown clinically meaningful benefits in lung function, dyspnea, and quality of life in patients with severe emphysema. Safety outcome data obtained after BLVR in the United States are scarce outside the RCTs.</p><p><strong>Research question: </strong>What is the rate of inpatient complications after BLVR in the real world in the United States?</p><p><strong>Study design and methods: </strong>We used the National Inpatient Sample database to identify in-hospital complications after BLVR from 2018 through 2020. Complications were defined as pneumothorax, COPD exacerbation, pneumonia, hemoptysis, acute respiratory failure, and valve removal. We also analyzed all-cause in-hospital mortality and length of stay (LOS).</p><p><strong>Results: </strong>We identified 467 admissions related to BLVR procedures. The number of procedures doubled between 2019 and 2020 (from 153 to 295 procedures). The median age was 67.9 years (interquartile range, 61.1-72.8 years), 210 patients (45.0%) were female, 401 patients (85.8%) were White, and Medicare was the primary expected payer for 72.8% of patients. Most procedures were performed in urban teaching hospitals (56.9%). The rate of pneumothorax was 26.3%, that of acute respiratory failure was 19.5%, that of COPD exacerbation was 8.8%, that of pneumonia was 7.3%, and that of hemoptysis was 5.3%. Chest tube placement was required in 84 of 123 patients (68.3%) with pneumothorax. The endobronchial valve had to be removed in 69 patients (14.8%). The median LOS was 2.8 days (interquartile range, 2.3-4.5 days). The number of in-hospital deaths was fewer than 11 (< 2.3%). Overall, the subgroup who experienced in-hospital complications did not differ significantly from the others in terms of comorbidities, demographics, and hospital characteristics.</p><p><strong>Interpretation: </strong>We found that the real-world complication rate after BLVR was similar to the published complication rates from early randomized clinical trials. In-hospital mortality was low, suggesting that aside from the commonly anticipated complications, BLVR is a safe treatment option for severe emphysema.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"436-443"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142055055","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Failure of Fibrinolytic Therapy in Empyema: Neutrophil Elastase Activity, High Plasminogen Activator Inhibitor 1, Both, or Neither?
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 DOI: 10.1016/j.chest.2024.09.039
Galina Florova, Andrey A Komissarov
{"title":"Failure of Fibrinolytic Therapy in Empyema: Neutrophil Elastase Activity, High Plasminogen Activator Inhibitor 1, Both, or Neither?","authors":"Galina Florova, Andrey A Komissarov","doi":"10.1016/j.chest.2024.09.039","DOIUrl":"https://doi.org/10.1016/j.chest.2024.09.039","url":null,"abstract":"","PeriodicalId":9782,"journal":{"name":"Chest","volume":"167 2","pages":"e63-e64"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"143405584","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
A Comparison of GOLD and STAR Severity Stages in Individuals With COPD Undergoing Pulmonary Rehabilitation. 接受肺康复治疗的慢性阻塞性肺病患者的 GOLD 和 STAR 严重程度分级比较。
IF 9.5 1区 医学 Q1 CRITICAL CARE MEDICINE Pub Date : 2025-02-01 Epub Date: 2024-10-19 DOI: 10.1016/j.chest.2024.10.013
Pasquale Ambrosino, Michele Vitacca, Giuseppina Marcuccio, Antonio Spanevello, Nicolino Ambrosino, Mauro Maniscalco

Background: Alongside the recognized Global Initiative for Obstructive Lung Disease (GOLD) classification, the Staging of Airflow Obstruction by Ratio (STAR) severity scheme has been proposed for categorizing COPD.

Study question: What are the agreement and utility of the GOLD and STAR classifications in patients with severe COPD entering the rehabilitation setting?

Study design and methods: Medical records were reviewed in this multicenter retrospective study, examining key functional variables and their changes in a large cohort of patients with COPD undergoing pulmonary rehabilitation.

Results: A total of 1,516 participants (33.7% female participants; median age, 72.0 years) were included in the analysis. Compared with GOLD, the use of the STAR classification resulted in a different disease severity category for 53.4% of patients. An unweighted Cohen's kappa of 0.25 and a Bangdiwala B value of 0.24 indicated a fair agreement between the 2 classifications. Higher weighted agreement measures (0.47 and 0.78, respectively) suggested that discrepancies between the classifications mainly occurred for contiguous stages. GOLD exhibited superior discrimination between stages for chronic respiratory failure, whereas STAR exhibited better performance in detecting hyperinflation. In terms of their application within pulmonary rehabilitation settings, GOLD exhibited superior performance compared with STAR in identifying the minimal clinically important difference in 6-min walking distance and modified Medical Research Council score. Accordingly, GOLD but not STAR acted as an independent predictor for achieving a minimal clinically important difference in modified Medical Research Council score (OR, 1.48; 95% CI, 1.12-1.94; P = .005) and also independently predicted changes in the Braden scale score (β = 0.154; P = .004).

Interpretation: STAR exhibited a more uniform gradation of disease severity and enhanced performance in detecting hyperinflation, but our preliminary findings do not endorse its utilization in the rehabilitation setting.

背景:除了公认的全球阻塞性肺病倡议(GOLD)分类外,还提出了按比例对气流阻塞(STAR)严重程度进行分期的方案,用于对慢性阻塞性肺病(COPD)进行分类:研究问题:GOLD 和 STAR 分类在进入康复机构的重度 COPD 患者中的一致性和实用性如何?这项多中心回顾性研究对病历进行了审查,研究了一大批接受肺康复(PR)治疗的 COPD 患者的主要功能变量及其变化:共有 1,516 名参与者(33.7% 为女性,中位年龄为 72.0 岁)参与了分析。与 GOLD 相比,使用 STAR 分级法可使 53.4% 的患者获得不同的疾病严重程度类别。非加权科恩κ值为0.25,Bangdiwala B值为0.24,显示两种分类方法的一致性尚可。较高的加权一致度(分别为 0.47 和 0.78)表明,分类之间的差异主要发生在连续的分期上。GOLD 对慢性呼吸衰竭的分期显示出更高的区分度,而 STAR 在检测过度充气方面表现更佳。在 PR 环境中的应用方面,GOLD 与 STAR 相比,在识别 6 分钟步行距离和改良医学研究委员会(mMRC)评分的最小临床重要性差异(MCID)方面表现更佳。因此,GOLD 而非 STAR 是实现 mMRC MCID 的独立预测因子(OR:1.48;95% CI:1.12-1.94;P=0.005),并且还能独立预测 Braden 评分的变化(β=0.154;P=0.004):STAR显示了更均匀的疾病严重程度分级,并提高了检测过度充气的性能,但我们的初步研究结果并不支持将其用于康复治疗。
{"title":"A Comparison of GOLD and STAR Severity Stages in Individuals With COPD Undergoing Pulmonary Rehabilitation.","authors":"Pasquale Ambrosino, Michele Vitacca, Giuseppina Marcuccio, Antonio Spanevello, Nicolino Ambrosino, Mauro Maniscalco","doi":"10.1016/j.chest.2024.10.013","DOIUrl":"10.1016/j.chest.2024.10.013","url":null,"abstract":"<p><strong>Background: </strong>Alongside the recognized Global Initiative for Obstructive Lung Disease (GOLD) classification, the Staging of Airflow Obstruction by Ratio (STAR) severity scheme has been proposed for categorizing COPD.</p><p><strong>Study question: </strong>What are the agreement and utility of the GOLD and STAR classifications in patients with severe COPD entering the rehabilitation setting?</p><p><strong>Study design and methods: </strong>Medical records were reviewed in this multicenter retrospective study, examining key functional variables and their changes in a large cohort of patients with COPD undergoing pulmonary rehabilitation.</p><p><strong>Results: </strong>A total of 1,516 participants (33.7% female participants; median age, 72.0 years) were included in the analysis. Compared with GOLD, the use of the STAR classification resulted in a different disease severity category for 53.4% of patients. An unweighted Cohen's kappa of 0.25 and a Bangdiwala B value of 0.24 indicated a fair agreement between the 2 classifications. Higher weighted agreement measures (0.47 and 0.78, respectively) suggested that discrepancies between the classifications mainly occurred for contiguous stages. GOLD exhibited superior discrimination between stages for chronic respiratory failure, whereas STAR exhibited better performance in detecting hyperinflation. In terms of their application within pulmonary rehabilitation settings, GOLD exhibited superior performance compared with STAR in identifying the minimal clinically important difference in 6-min walking distance and modified Medical Research Council score. Accordingly, GOLD but not STAR acted as an independent predictor for achieving a minimal clinically important difference in modified Medical Research Council score (OR, 1.48; 95% CI, 1.12-1.94; P = .005) and also independently predicted changes in the Braden scale score (β = 0.154; P = .004).</p><p><strong>Interpretation: </strong>STAR exhibited a more uniform gradation of disease severity and enhanced performance in detecting hyperinflation, but our preliminary findings do not endorse its utilization in the rehabilitation setting.</p>","PeriodicalId":9782,"journal":{"name":"Chest","volume":" ","pages":"387-401"},"PeriodicalIF":9.5,"publicationDate":"2025-02-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142459119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Chest
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1